

**DESCRIPTION**

<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human Adenosylhomocysteinase/AHCY in direct ELISAs and Western blots.
<b>Source</b>	Polyclonal Sheep IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	<i>E. coli</i> -derived recombinant human Adenosylhomocysteinase/AHCY Ser2-Tyr432 Accession # P23526
<b>Conjugate</b>	Alexa Fluor 594 Excitation Wavelength: 590 nm Emission Wavelength: 617 nm
<b>Formulation</b>	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide  *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

**APPLICATIONS**

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

**Western Blot** Optimal dilution of this antibody should be experimentally determined.

**PREPARATION AND STORAGE**

**Shipping** The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

**Stability & Storage** Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

**BACKGROUND**

Human S-Adenosylhomocysteinase (AHCY) is a cytoplasmic tetramer with a tightly bound NAD co-factor for each subunit (1, 2). It is the only known enzyme to catalyze the breakdown of S-adenosylhomocysteine (AdoHcy) to homocysteine and adenosine. AdoHcy hydrolysis is a reversible reaction with an equilibrium favoring AdoHcy formation, but hydrolysis prevails under physiological conditions due to the rapid removal of adenosine and homocysteine. Thus, AHCY's activity in mammals is directly related to homocysteine level, an independent risk factor for vascular disease (3). It also functions as a regulator of biological transmethylation by controlling the concentration of AdoHcy, a potent competitive inhibitor of all S-adenosyl-L-methionine methyltransferases (1). A mutation in the human AHCY results in AHCY deficiency with increase of plasma creatine kinase, methionine, S-adenosylmethionine and AdoHcy, delay of myelination, myopathy and psychomotor retardation (4, 5).

**PRODUCT SPECIFIC NOTICES**

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.